



ORIGINALS

Bilingual edition English/Spanish

Cost-effectiveness of drug therapy prescribed in special situations at hospital

Coste-efectividad de los medicamentos en situaciones especiales en un hospital

Gonzalo González-Morcillo, Beatriz Calderón-Hernanz, Juan Manuel Rodríguez-Camacho

Servicio de Farmacia, Hospital Universitario Son Llàtzer, Palma de Mallorca. Spain.

Author of correspondence

Gonzalo González Morcillo
Servicio de Farmacia,
Hospital Universitario Son Llàtzer
Carretera de Manacor, km 4
07198 Palma de Mallorca, Spain.

Email:
ggonzalezmorcillo@gmail.com

Received 10 April 2020;
Accepted 29 May 2020.
DOI: 10.7399/fh.11451

How to cite this paper

González-Morcillo G, Calderón-Hernanz B, Rodríguez-Camacho JM. Cost-effectiveness of drug therapy prescribed in special situations at hospital. Farm Hosp. 2020;44(6):272-8.

Abstract

Objective: The Pharmacy and Therapeutics Committee is an advisory body to the medical management of our hospital. Following Royal Decree 86/2015, which regulates the Pharmacy and Therapeutics Committee of the Balearic Islands, this committee prepared a technical report in which it assessed the possible internal use of off-label drugs, drugs for compassionate use, and drugs not included in the hospital's pharmacotherapeutic guide. The objective was to analyse the clinical response achieved with the use of these drugs and their associated costs.

Method: Retrospective study of drugs whose use was requested from the hospital's Pharmacy and Therapeutics Committee hospital between January and December 2018. We analysed whether the requested treatment achieved the objective established by the physician. The cost was calculated based on the duration of the treatment until the objective was achieved or until treatment was discontinued.

Results: In total, 70 requests were analysed: 59% achieved the expected therapeutic goal, 34% were considered to be therapeutic failures, and 7% were lost to follow-up. The overall cost of the 70 authorized treatments was €1,140,240. The average cost per request was €16,288. Oncology and Haematology services submitted more than 50% of the requests, and more than 75% of the budget was allocated to these medical services.

Resumen

Objetivo: La Comisión de Farmacia y Terapéutica, como órgano asesor de la Dirección Médica del hospital y bajo las condiciones del Real Decreto 86/2015, por el que se regula la Comisión de Farmacoterapéutica de las Islas Baleares, elabora un informe técnico donde evalúa la posibilidad de empleo interno de medicamentos *off-label*, uso compasivo y medicamentos no incluidos en la Guía Farmacoterapéutica del hospital. Asimismo, esta comisión realiza un seguimiento prospectivo de cada una de las solicitudes. El objetivo fue analizar la respuesta clínica alcanzada con el empleo de estos medicamentos, así como el coste asociado.

Método: Estudio retrospectivo de los medicamentos solicitados a la Comisión de Farmacia y Terapéutica del hospital entre enero y diciembre de 2018. Se analizó si con cada tratamiento solicitado se alcanzó el objetivo propuesto por el clínico. Para el cálculo del coste se consideró la duración del tratamiento hasta alcanzar el objetivo propuesto o hasta su interrupción.

Resultados: De un total de 70 solicitudes analizadas, un 59% alcanzaron el objetivo terapéutico esperado, un 34% fueron consideradas como fracaso terapéutico y hubo un 7% de pérdidas de seguimiento. El coste de las 70 peticiones fue de 1.140.240 €. La media de coste por solicitud fue de 16.288 €. Más del 50% de las solicitudes fueron realizadas por los servicios de oncología y hematología y más del 75% del presupuesto fue destinado a estos dos servicios.

KEYWORDS

Pharmacy and Therapeutics Committee; Pharmacotherapeutic Guide; Off-label use; Compassionate Use Trials; Assessment Studies; Clinical Audit; Outcome and Process Assessment; Health Care.

PALABRAS CLAVE

Comisión de Farmacia y Terapéutica; Guía Farmacoterapéutica; Usos fuera de indicación; Ensayos de uso compasivo; Informes de evaluación; Auditoria clínica; Resultados en salud; Atención sanitaria.



Los artículos publicados en esta revista se distribuyen con la licencia
Articles published in this journal are licensed with a
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
<http://creativecommons.org/licenses/by-nc-sa/4.0/>
La revista Farmacia no cobra tasas por el envío de trabajos,
ni tampoco por la publicación de sus artículos.

Conclusions: More than half of the treatments analysed by the Pharmacy and Therapeutics Committee of the hospital achieved their therapeutic goal, although the economic cost of their use was high.

Introduction

The Spanish Royal Decree 1015/2009 (RD) regulated the availability of medications for special situations (MSS)¹ and led to two major changes: redefining the uses of some drugs, and modifying the procedure required for their acquisition.

Regarding the redefinition of use, three special situations were clearly defined:

- Access to investigational medicinal products for patients outside a clinical trial and without authorised therapeutic alternatives (compassionate use of investigational medicinal products).
- The use of drugs under conditions other than those authorised (off-label).
- The use of drugs approved in other countries but not in Spain, generally for marketing reasons (i.e. foreign drugs).

Regarding procedural modifications, the need for individual authorisation by the Spanish Agency of Medicines and Medical Devices (AEMPS) on a case-by-case basis was eliminated and transferred to health care centres.

Another special situation refers to drugs that have been approved by the AEMPS for a particular indication, but are not included in the hospital's Pharmacotherapy Guidelines (HPG), and that at the time of request are not included in the HPG for their prescription to patients from a specific autonomous community or patients treated in hospitals.

The work of hospital PTCs²⁻⁵ has been driven by the need to justify the use of MSSs or drugs not included in the HPG, and to inform patients of potential benefits and risks to obtain their informed consent. In our hospital, this activity was defined in the Spanish RD 86/2015, which creates and regulates the composition, organisation, and running of the PTC in the Balearic Islands⁶. Blanco-Reina *et al.*⁷ and a French consensus document that assessed medicines⁸ have suggested that the large volume of off-label prescriptions requires follow-up concerning the effectiveness and costs of MSSs not included in the HPG. However, very few studies have assessed the results obtained from the use of these medications in terms of effectiveness, safety, and associated costs⁹⁻¹³.

The main objective of this study was to analyse the clinical response to the use of these drugs and their costs. The secondary objective was to describe the use and type of medications requested by the medical services.

Methods

Retrospective study conducted in a secondary care hospital within a health area serving 265,000 inhabitants. The analysis included drugs for compassionate use, off-label drugs, and drugs not included in the HGP (non-HPG medications) whose use was requested from the hospital PTC from January 2018 to December 2018. Although foreign medications may be classified as MSSs, requests for these drugs were excluded because they are not processed by our hospital's PTC. The follow-up period for each request processed was established according to the expected outcome of the treatments.

In order to comply with the requirements of the RD¹⁻⁵, we designed Standard Operating Procedures (SOP), which were submitted to and approved by the PTC. According to the SOP, the PTC assumes responsibility for assessing the internal use of off-label, compassionate use, and non-HPG medications. The SOP consists of the following stages:

1. Creation of the request: the responsible physician makes an electronic request for the patient's new medical treatment. The report includes the following information: medication requested, dosage, indication, treatment outcome expected by the physician, bibliographic references justifying its use, the patient's clinical report, and informed consent.

Conclusiones: Más de la mitad de los tratamientos considerados por la Comisión de Farmacia y Terapéutica del hospital alcanzan la finalidad terapéutica deseada, si bien el impacto económico de su empleo es elevado.

2. Assessment of the request: the Pharmacy Service (PS) receives the physician's electronic request for the MSS and prepares a technical report that includes the following: an analysis of the available evidence on indications for the drug requested; alternatives with an approved indication; alternatives with a nonapproved indication, but with greater scientific evidence; analysis of the economic impact; and proposal for authorization/rejection. The report is then submitted for review and assessment by the members of the PTC.

3. Resolution of requests: each request is assessed during the monthly PTC meeting. Each request includes the pharmacist's technical report and the requesting physician's clinical report. The PTC issues a final decision which, in the event of approval, must be validated by the hospital's Medical Director.

To investigate the clinical response to each treatment, the PS used Microsoft Access 2007 to design a database in which each drug request was recorded. The variables collected were as follows: medical service, drug, indication, type of request, treatment objective, response to treatment based on whether the objective proposed by the physician was achieved or not, and cost. All data were obtained from the electronic medical record and the integrated drug management system of the PS.

Therapeutic success was defined as the response to treatment matching the objective proposed by the physician in their request form. Therapeutic failure was defined as failure to achieve the clinical objective by the date agreed at the PTC meeting.

All data analyses were conducted using SPSS v.23 software. Study variables were described as tabulated data. Continuous variables are expressed as a means and categorical variables are expressed as estimated total percentages and frequencies. The cost analysis was based on the duration of treatment until therapeutic success was achieved or, failing this, on the number of doses administered until treatment was discontinued. The amount entered in the cost analysis was the price paid by the hospital (company selling price - discounts + VAT).

All the data were collected by a researcher. The request underwent external review by the PTC as well as by the pharmacist responsible for the medical service making the request.

Results

We analysed 70 requests accepted by the PTC during the study period. Table 1 shows the requests classified by medical service requesting the MSS. The most requests were made by medical oncology (26 requests), haematology (11), and dermatology (10), which together comprised 67% of all requests. Regarding the type of request, 69% were for off-label drugs, 20% were non-HPG medications, and 11% were requests for compassionate use.

Therapeutic success was achieved in 59% (41 requests) of cases. Therapeutic failure occurred in 34% (24 requests) of cases: that is, the clinical outcomes expected by the physicians were not achieved. In total, 7% of the requests could not be analysed due to loss to follow-up: there were 3 deaths due to causes unrelated to the disease or the treatment received, 1 case in which the patient moved to another autonomous community, making follow-up impossible, and 1 case in which the patient refused to initiate treatment after it had been approved by the PTC. Figure 1 shows the clinical outcomes by medical service requesting the MSS.

The total cost of the treatments for the 70 requests for special medications and medications not included in HPG was €1,140,240. The cost of the treatments analysed was €821,631, of which €521,250 (63%) corresponded to therapeutic success and €300,381 corresponded to therapeutic failure (37%). The average cost per treatment request was €16,288. One of the treatments requested by the haematology service, inotuzumab + rituximab (cost = €259,764), was excluded from this calculation in order to

Table 1. Requests classified by medical service

Medical service	Active ingredient	Indication	Type of request	Objective of the treatment
Dermatology	Apremilast	Severe atopic dermatitis	Off-label	To manage symptoms To reduce steroid use
	Dapsone	Mild/moderate hidradenitis suppurativa	Off-label	Significant clinical improvement (Hurley's severity scale)
	Dupilumab	Severe atopic dermatitis	Compassionate use	To manage symptoms To reduce steroid use
	Dupilumab	Severe atopic dermatitis	Compassionate use	To manage symptoms To reduce steroid use
	Etanercept	Pityriasis rubra pilaris	Off-label	To eliminate skin lesions
	Rituximab	Refractory pemphigus vulgaris	Off-label	To eliminate skin lesions in 6 mo
	Rituximab	Refractory pemphigus vulgaris	Off-label	To eliminate skin lesions in 6 mo
	Intralesional rituximab	Marginal zone lymphoma	Off-label	To eliminate skin lesions To avoid recurrence at 14 mo
	Ustekinumab	Resistant hidradenitis suppurativa	Off-label	To reduce symptoms according to the Sartorius staging system
Gastrointestinal	Ustekinumab	Acrodermatitis continua of Hallopeau	Off-label	To eliminate skin lesions in 6 mo
	Nitazoxanide	Norovirus infection in primary immunodeficiency	Off-label	Obtain negative norovirus levels
Haematology	Bevacizumab	Rendu-Osler syndrome	Off-label	To decrease bleeding and administration of intravenous iron
	Carfilzomib + daratumumab + dexamethasone	Multiple myeloma relapsing after multiple lines of chemotherapy	Off-label	To achieve PFS at 14 mo
	Daratumumab + cyborD	Multiple myeloma and amyloidosis	Off-label	To obtain complete haematological response according to criteria in study NCT03201965
	Daratumumab + pomalidomide + dexamethasone	Multiple myeloma with poor cytogenetic prognosis	Off-label	To achieve PFS at 8 mo
	Ibrutinib + rituximab + bendamustina	Refractory diffuse large B-cell lymphoma (DLBCL)	Off-label	To achieve PFS at 8 mo
	Ibrutinib + obinutuzumab	Refractory DLBCL	Off-label	To achieve tumour response as defined in clinical study NCT00849654
	Inotuzumab + rituximab	DLBCL (c-myc) 2nd relapse after APBSCT	Off-label	To achieve PFS at 18 mo
	Nivolumab	Refractory Hodgkin's lymphoma	Compassionate use	To achieve PFS at 12 mo
	Ponatinib	Blast crisis in chronic myeloid leukaemia	Off-label	To achieve DFS at 1 y
	Rituximab + lenalidomide	Progressing DLBCL after 3 treatment lines	Off-label	To achieve OS at 10 mo
Internal Medicine	Venetoclax	Refractory mantle cell lymphoma	Off-label	To achieve PFS at 12 mo
	Rituximab	Anti-MDA5+ amyopathic dermatomyositis	Off-label	To manage symptoms
	Tocilizumab	Refractory Behçet's disease	Off-label	To manage symptoms To reduce steroid use
Nephrology	Rituximab	Primary membranous nephropathy	Off-label	To manage symptoms
	Tolvaptan	Autosomal dominant polycystic kidney disease	Off-label	To inhibit kidney damage
	Tolvaptan	Cardiorenal syndrome type 2 (CRS-2)	Off-label	To reduce the number of hospital admissions
	Tolvaptan	CRS-2	Off-label	To reduce the number of hospital admissions
	Tolvaptan	CRS-2	Off-label	To reduce the number of hospital admissions
Neurology	Interferon beta 1a	Balo Disease	Off-label	To prevent flares

Table 1 (cont.). Requests classified by medical service

Medical service	Active ingredient	Indication	Type of request	Objective of the treatment
Oncology	Alectinib	ALK-positive lung cancer	Not included in the HPG	To achieve PFS at 18 mo
	Atezolizumab	Urothelial carcinoma resistant to 2nd-line treatment	Not included in the HPG	To achieve PFS at 12 mo
	Atezolizumab	Urothelial carcinoma resistant to 3rd-line treatment	Not included in the HPG	To achieve PFS at 12 mo
	Atezolizumab	Metastatic urothelial carcinoma resistant to 1st-line treatment	Not included in the HPG	To achieve PFS at 3 mo To achieve OS at 12 mo
	Cabozantinib	Renal carcinoma resistant to 1st-line treatment	Not included in the HPG	To achieve PFS at 8 mo
	Capecitabine	Endocervical squamous cell carcinoma	Off-label	To achieve PFS at 4 mo
	Capecitabine	Adjuvant therapy for HER-2+ breast cancer	Off-label	To achieve PFS at 18 mo
	Capecitabine	Adjuvant therapy for HER-2+ breast cancer	Off-label	To achieve PFS at 18 mo
	Dabrafenib + trametinib + cyBord	Advanced thyroid carcinoma	Off-label	To achieve OS at 10 mo
	Durvalumab	Stage IIIA lung adenocarcinoma with partial response after ChT	Compassionate use	To achieve PFS at 16 mo
	Durvalumab	Stage IIIB lung adenocarcinoma with partial response after ChT	Compassionate use	To achieve PFS at 16 mo
	Durvalumab	Stage IIIA lung adenocarcinoma with partial response after ChT	Compassionate use	To achieve PFS at 16 mo
	Pegylated liposomal irinotecan	Metastatic pancreatic adenocarcinoma resistant to 2nd-line treatment	Not included in the HPG	To achieve OS at 6 mo
	Ipilimumab + Nivolumab	Locally advanced unresectable adenocarcinoma of the colon	Off-label	To achieve OS at 12 mo
	Nivolumab	Adjuvant in malignant stage IIIB melanoma	Off-label	To achieve PFS at 12 mo
	Nivolumab	Head and neck squamous cell carcinoma resistant to platinum	Not included in the HPG	To achieve OS at 7 mo
	Nivolumab	Head and neck squamous cell carcinoma resistant to platinum	Not included in the HPG	To achieve OS at 7 mo
	Osimertinib	EGFR+T790M non-small cell lung cancer	Not included in the HPG	To achieve PFS at 10 mo
	Palbociclib	Neo breast cancer ER+/HER-in progression + fulvestrant + goserelin	Not included in the HPG	To achieve PFS at 11 mo
	Palbociclib	Neoadjuvant neo breast cancer + anastrozol	Off-label	To achieve RCB 0-1 (residual cancer burden)
	Palbociclib	Neo breast cancer ER+/HER-in progression + letrozol	Not included in the HPG	To reach PFS at 11 months
	Palbociclib	Neo breast cancer ER+/HER-in progression + letrozol	Not included in the HPG	To achieve PFS at 11 mo
	Palbociclib	Neoadjuvant neo breast cancer + anastrozol	Off-label	To achieve RCB 0-1 (residual cancer burden)
	Pertuzumab	Adjuvant treatment in HER2+ breast cancer with high risk of relapse	Not included in the HPG	To achieve PFS at 12 mo
	Pembrolizumab	Neoadjuvant for bladder cancer relapse	Not included in the HPG	To achieve OS at 10 mo
	Pembrolizumab	Neoadjuvant colon cancer with peritoneal carcinomatosis in progression	Off-label	To achieve OS at 6 mo

Table 1 (cont.). Requests classified by medical service

Medical service	Active ingredient	Indication	Type of request	Objective of the treatment
Otorhinolaryngology	Cidofovir	Recurrent laryngeal papillomatosis	Off-label	Recurrence-free survival at 18 mo
	Cidofovir	Recurrent laryngeal papillomatosis	Off-label	Recurrence-free survival at 18 mo
Paediatrics	Human chorionic gonadotropin	Idiopathic short stature	Off-label	To stimulate growth To achieve adult height 146.7 ± 5 cm
	Hydroxybutyrate	Severe scoliosis due to metabolic myopathy with multiple acyl-CoA dehydrogenase deficiency	Off-label	No alternative
	Miglustat	Sandhoff disease	Off-label	Inhibit the progression of neurodegenerative processes
	Romiplostin	Chronic primary immune thrombocytopenic purpura	Off-label	To normalise platelet count
Rheumatology	Apremilast	Refractory Behçet disease	Off-label	To manage symptoms To reduce steroid use
	Rituximab	Dermatomyositis	Off-label	To manage symptoms
	Tocilizumab	Refractory Behçet disease	Off-label	To manage symptoms To reduce steroid use
Traumatology	Tedizolid	Chronic osteomyelitis	Off-label	To resolve infection
Pain Unit	Capsaicin 8% patches	Chronic neuropathic pain	Off-label	To provide improved pain control
Urology	Abiraterone	Metastatic hormone-sensitive prostate cancer	Compassionate use	To achieve OS at 3 y
	Abiraterone	Metastatic hormone-sensitive prostate cancer	Compassionate use	To achieve OS at 3 y

APBSCT: autologous peripheral blood stem cell transplantation; ChT: chemotherapy; DFS: disease free survival; DLBCL: diffuse large B-cell lymphoma; HPG: hospital Pharmacotherapy Guidelines; OS: overall survival; PFS: progression free survival.

avoid distorting the results. Figure 2 shows the cost per request by medical service.

Of the 41 requests in which therapeutic success was achieved, 30 were off-label requests, 4 were non-HPG medications, and 7 were drugs for compassionate use. Of note, 75% of the medications were cytostatic and biologic drugs.

Discussion

The assessment of MSSs or non-HPG drugs is a relevant activity, which is currently conducted by hospital PTCs. This study analysed a total of 70 requests approved by our PTC over one year, which is equivalent to almost 6 requests per month.

Off-label prescriptions, the compassionate use of drugs, and the use of non-HPG drugs make it possible for patients to gain benefit from potentially effective treatments. However, off-label and compassionate use also entails a certain level of risk due to the fact that no safety guarantees have been issued by regulatory agencies because the risk-benefit ratios of these therapies have not been analysed for some diseases. The health care system has to invest in treatments for which there is limited evidence concerning their clinical benefits^{14,16}. RD 1015/2009 addressed these aspects and regulated the procedure¹ such that it is used under exceptional circumstances and is restricted to situations in which there are no therapeutic alternatives.

Despite these aspects, previous authors have stated that this type of prescribing is a common practice^{17,18}, and is particularly frequent, although for different reasons, in the fields of oncology and paediatrics^{15,16,19}.

Figure 1. Clinical results of treatment by medical service.





Figure 2. Average cost of requests by medical service.



There are several situations that may explain the prescription of off-label and non-HPG medications: delays in publishing the results of clinical research and the subsequent authorisation of a new indication by the regulatory agencies; the exclusion from clinical trials of certain groups of patients due to ethical limitations; the lack of interest among manufacturers in registering a new indication; and delays between the time of approval by the AEMPS and the time of approval by the PTCs such that the drugs can be made available in hospitals^{19,21}.

On the other hand, before new and effective but very expensive drugs can be released, the available data needs to be collected and analysed in order to decide as quickly as possible whether these drugs have therapeutic value. The use of MSSs can be improved by monitoring and the creation of records of real-world results. Out of the total number of requests, 59% of the treatments led to therapeutic successes and 7% were lost to follow-up.

It is difficult to compare the results of our study with those of others because of the low number of studies that have assessed the health outcomes of using MSSs and non-HPG drugs.

The multicentre study by Danés *et al.*⁹ included the assessment of 232 MSSs for 102 different indications. In relation to therapeutic success, their results were similar to ours: complete response to treatment (31.4%), partial response to treatment (36.3%), and stabilization (4.9%). However, their study addressed different diseases and used different drugs, thus making it impossible to compare the results.

The present study shows that most requests were emitted by the departments of oncology and haematology, which obtained therapeutic success in 49% of cases (18 out of 37 requests). We compared our results to those of a descriptive observational retrospective study conducted by Arroyo Álvarez *et al.*¹³, who analysed 154 antineoplastic drugs that had been used in special situations between 2005 and 2015. Regarding treatment, they found a subjective response of 32.5% and an objective response of 10.7%. These authors noted that most of the drugs were used for the treatment of metastatic tumours. Differences in response rates between our study and theirs may be because our study did not include many patients with metastatic tumours.

Our study also shows that the dermatology service emitted the third highest number of requests (10), of which 9 led to therapeutic success. This result is much higher than that obtained by Ong *et al.*¹², who obtained therapeutic success in 70% of the 25 off-label requests from the dermatology service. This difference could be explained by the fact that in the study by Ong *et al.* 20% of patients had to discontinue treatment due to adverse events.

Another relevant aspect of the use of MSSs is their economic impact on the health care budget and its sustainability. Our analysis shows that, over the study period, the actual cost of the treatments was more than €1 million. We compared the average cost per request in our study with that of the study conducted by Arocas Casañ *et al.*²². Their study assessed the economic impact of 834 requests for MSSs and obtained a cost per request/y of €8,554. In our study, the average cost per request/y was €16,288, which is almost double the figure reported by these authors. This result may be because many of our treatments were administered for more than one year, whereas Arocas Casañ *et al.* calculated the average annual cost.

In the setting of dermatology, a comparison of our cost per request and that of Ong *et al.*¹² shows that the costs per request/y were €4,348 and €2,755, respectively. There are two reasons for this difference. Firstly, we estimated the cost of the full treatment rather than the yearly cost of the treatment. Secondly, in the study by Ong *et al.*, 20 of the 25 requests were for thalidomide, mycophenolate mofetil, and cyclosporine, which have lower costs than those requested in our study.

When assessing the cost-benefits of the all the treatments assessed, excluding the 7% lost to follow-up, we found that 63% of the budget was spent on treatments that achieved therapeutic success. As Ong *et al.*¹² suggested, the costs of these drugs may be offset by a decrease in the number of times patients are admitted to hospital (i.e. lower morbidity with improved quality of life) and by the use of alternative treatments.

In our hospital, half of the requests were made by the haematology and oncology services and accounted for more than 75% of the budget for MSSs and non-HPG drugs. This result could be due to the upsurge in these

areas of research and the rapid dissemination of results from clinical trials before these drugs are approved by the regulatory agencies¹⁹.

Of note, there were few requests from the paediatric medical services in our study. The literature suggests that the prescription rate for off-label drugs is more than 50%^{23,24}. However, only 4 out of the 70 requests assessed by our PTC were destined for paediatric use. This disparity is probably due to our hospital not being a Maternity and Children's hospital. Nevertheless, it could also be due to possible under-reporting to the hospital's PTC.

This study has some limitations. Firstly, the results cannot be generalized. Secondly, extrapolation would be complex because of the heterogeneous diseases and drugs included in the study and the low number of cases in each disease or drug group. Nevertheless, it presents a reliable picture of the situation in our hospital, while increasing our knowledge of the real-world results of the use of these drugs, thus providing the scientific community with evidence on this topic.

The aim of this study was to design a model for managing MSSs and non-HPG medications, while complying with the regulations described in RD 1015/2009 and RD 86/2015. The assessment and monitoring procedure proposed by the multidisciplinary PTC ensures that ethical factors are taken into account during decision-making and that access to treatment is based on best evidence for the patient and cost-effectiveness. Prospective monitoring of the patient during treatment makes it possible to re-evaluate the patient if the objective of the physician is not being achieved. It also makes it possible to measure whether care is providing value, where value is understood as clinical benefit.

In conclusion, in our hospital, more than half of the MSSs and non-HPG medications met their therapeutic objectives, although the economic impact of their use was high.

Funding

No funding.

Conflicts of interest

No conflicts of interests.

Presentation at Congresses

Presentation as operational communication (poster format) of the results obtained as of December 31, 2018, under the title "Implementation of an evaluation and monitoring circuit in special situations" at the 64th National Congress of the Spanish Society of Hospital Pharmacy (SEFH) in Seville (Spain), October 17-19, 2019.

Contribution to the scientific literature

The prescription of medications for special situations, off-label drugs, or drugs for compassionate use, is a common and widespread practice that allows patients to benefit from a potentially effective treatment. However, this practice entails certain risks, because these drugs are used in conditions in which there is insufficient evidence to guarantee a positive risk-benefit ratio. Thus, their use must be properly explained to patients, who are required to give their informed consent. Experts in medication surveillance strongly recommend strict follow-up and monitoring during these treatments. Despite this, few studies have assessed the health outcomes obtained from the use of these drugs.

The present study analysed a model for managing medications for special situations, such as off-label drugs and drugs not included in our hospital's Pharmacotherapy Guidelines. Requests for the use of these drugs were sent to the hospital's Pharmacy and Therapeutics Committee. The Pharmacy and Therapeutics Committee assessed and monitored the requests to ensure that each treatment was based on best evidence and cost-effectiveness to guarantee that both patients and the health care system obtained benefits. The monitoring and creation of records of real-world results and the appropriate analysis of outcomes can contribute to the development of strategies to improve the rational and reasonable use of these drugs.

Bibliography

1. Real Decreto 1015/2009, de 19 de julio de 2009, por el que se regula la disponibilidad de medicamentos en situaciones especiales. Boletín Oficial del Estado, n.º 174 [20 de julio de 2009].
2. Avendaño Solá C. Uso compasivo de medicamentos: un cambio necesario en España. *Med Clin (Barc)*. 2009;133:425-6. DOI: 10.1016/j.medcli.2009.07.003
3. Delgado O, Puigventos F, Clopés A. Posicionamiento del farmacéutico de hospital ante la utilización de medicamentos en condiciones diferentes a las autorizadas. *Farm Hosp*. 2009;33:237-9.
4. Ley 41/2002, de 14 de noviembre, básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica. Boletín Oficial del Estado, n.º 274 [15 de noviembre de 2002].
5. Pérez-Moreno MA, Villalba-Moreno AM, Santos-Ramos B, Marín-Gil R, Varela-Aguilar JM, Torello-Iserte J, et al. Off-label approval of drug use in a tertiary hospital. *Rev Calid Asist*. 2013;28(1):12-8. DOI: 10.1016/j.cali.2012.05.005
6. Real Decreto 86/2015, de 23 de octubre, por el que se crea la Comisión Farmacoterapéutica del Servicio de Salud de las Illes Balears y se regula su composición, organización y funcionamiento. Boletín Oficial de las Islas Baleares, n.º 155 [25 de octubre de 2015].
7. Blanco-Reina E, Muñoz-García A, Cárdenas-Aranzana MJ, Ocaña-Riola R, Pradolongo JR. Assessment of off-label prescribing: profile, evidence and evolution. *Farm Hosp*. 2017;41(4):458-69. DOI: 10.7399/fh.2017.41.4.10562
8. Benoît Murlat B. Les assises du médicament. Rapport de synthèse des Assises du médicament. Groupe 3. France : Ministère des Solidarités et de la Santé [Internet]; 2011 [accessed 08/12/2019]. Available at: https://solidarites-sante.gouv.fr/IMG/pdf/VOLUME_V_groupe_3-1.pdf
9. Danés I, Agustí A, Vallano A, Alerany C, Martínez J, Bosch JA, et al. Outcomes of off-label drug uses in hospitals: a multicentric prospective study. *Eur J Clin Pharmacol*. 2014;70(11):1385-93. DOI: 10.1007/s00228-014-1746-2
10. Chay J, Donovan P, Cummins S, Kubler P, Pillans P. Experience with low dose rituximab in off-label indications at two tertiary hospitals. *Int Med J*. 2013;43:871-82. DOI: 10.1111/imj.12207
11. Kesselheim A, Myers J, Solomon D, Winkelmayer W, Levin R, Avorn J. The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs. *PLoS ONE*. 2012;7(2):e31894. DOI: 10.1371/journal.pone.0031894
12. Ong N, McMeniman E, Pillans P, Soyer H. A clinical audit of high-cost and off-label drug use in dermatology. *Australas J Dermatol*. 2015;58(1):30-4. DOI: 10.1111/ajd.12392
13. Arroyo Álvarez C, Rodríguez Pérez L, Rodríguez Mateos ME, Martínez Bautista MJ, Benítez Rodríguez E, Baena-Cañada JM. Off-label antineoplastic drugs. An effectiveness and safety study. *Farm Hosp*. 2017;41(3):382-90. DOI: 10.7399/fh.2017.41.3.10745
14. Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. *BMC Med*. 2013;11:238. DOI: 10.1186/1741-7015-11-238
15. Falabregues A, Daul M, Pourroy B, Gauthier-Villano L, Pisano P, Rathelot P, et al. Pertinence des prescriptions «hors AMM/RTU» des molécules onéreuses dans un hôpital universitaire. *Thérapies*. 2015;70(5):385-402.
16. Smieliauskas F, Sharma H, Hurley C, de Souza J, Shih Y. State insurance mandates and off-label use of chemotherapy. *Health Economics*. 2017;27(1):e55-70. DOI: 10.1002/hec.3537
17. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course. Evidence and ethical off-label prescribing. *Arch Intern Med*. 2009;169:1745-7. DOI: 10.1001/archinternmed.2009.314
18. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. *Pharmacotherapy*. 2008;28:1443-52. DOI: 10.1592/phco.28.12.1443
19. Saiyed M, Ong P, Chew L. Off-label drug use in oncology: a systematic review of literature. *J Clin Pharm Ther*. 2017;42(3):251-8. DOI: 10.1111/jcpt.12507
20. Orloff JJ, Stanski D. Innovative approaches to clinical development and trial design. *Ann Ist Super Sanità*. 2011;47:8-13. DOI: 10.4415/ANN_11_01_03
21. Kwint P. Off-label drugs use in children-clinical perspective. *Przegl Lek*. 2011;68:1-3.
22. Arocas Casañ V, Mateo Carmona J, García Molina O, Fernández de Palencia Espinosa MA, Blázquez Álvarez MJ, de la Rubia Nieto MA, et al. Off-label prescription of drugs at hospital. *Farm Hosp*. 2016;40(2):63-78. DOI: 10.7399/fh.2016.40.2.9268
23. García-López I, Fuentes-Ríos J, Manrique-Rodríguez S, Fernández-Llamazares C. Utilización de medicamentos en condiciones off-label y unlicensed: resultados de un estudio piloto realizado en una unidad de cuidados intensivos pediátricos. *An Pediatr (Barc)*. 2017;86(1):28-36. DOI: 10.1016/j.anpedi.2016.01.026
24. Allen HC, Garbe MC, Lees J, Aziz N, Chaaban H, Miller JL, et al. Off-label Medication use in Children, More Common than We Think: A Systematic Review of the Literature. *J Okla State Med Assoc*. 2018;111(8):776-83.